11/8/26 Accelerated Pathways and Global Harmonization Previous Leveraging Natural History and RWE for Rare Approvals Next Mock Formal FDA Meeting: How to Respond When FDA Disagrees You Might Also Like Inside the FDA Mindset - Negotiating Endpoints and Surrogates Leveraging Natural History and RWE for Rare Approvals From Data to Discovery: Finding the Right Patients Across the Therapy Lifecycle From Awareness to Activation - Converting Rare Patient Identification into Trial Enrollment Commercial Success in Rare Disease Takes an Ecosystem: Aligning Manufacturers, Specialty Pharmacy, Providers, and Patient Support
11/8/26 Accelerated Pathways and Global Harmonization Previous Leveraging Natural History and RWE for Rare Approvals Next Mock Formal FDA Meeting: How to Respond When FDA Disagrees You Might Also Like Inside the FDA Mindset - Negotiating Endpoints and Surrogates Leveraging Natural History and RWE for Rare Approvals From Data to Discovery: Finding the Right Patients Across the Therapy Lifecycle From Awareness to Activation - Converting Rare Patient Identification into Trial Enrollment Commercial Success in Rare Disease Takes an Ecosystem: Aligning Manufacturers, Specialty Pharmacy, Providers, and Patient Support
